Justin R. Kulchycki
Van Andel Institute(US)Oakland University(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Multiple and Secondary Primary Cancers, Urinary and Genital Oncology Studies, Epigenetics and DNA Methylation
Most-Cited Works
- → Low Dose Brain Irradiation Reduces Amyloid-β and Tau in 3xTg-AD Mice(2020)43 cited
- → A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2023)35 cited
- → RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer(2023)25 cited
- → Data from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2023)2 cited
- → Figure S8 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2023)
- → Figure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2023)
- → Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2024)
- → Figure S3 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2023)
- → Figure S6 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy(2023)